Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | LYN | P07948 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | MARK3 | P27448 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29973546 | 1.00 | ALDH1A1 (0.61) | ALDH1A1TDP1MAPTCRHBPCRHR2 | |
| SCHEMBL11908199 | 0.83 | RPS6KA3 (0.43) | ALDH1A1TDP1MAPTHTTRAB9A | |
| SCHEMBL29939436 | 0.83 | ALDH1A1 (0.57) | ALDH1A1TDP1MAPTHTTRAB9A | |
| SCHEMBL28763125 | 0.83 | RPS6KA3 (0.58) | ALDH1A1TDP1MAPTHTTRAB9A | |
| SCHEMBL3591834 | 0.83 | ALDH1A1 (0.57) | ALDH1A1TDP1MAPTHTTRAB9A | |
| SCHEMBL4952534 | 0.83 | AHR (0.42) | ALDH1A1TDP1MAPTHTTRAB9A | |
| SCHEMBL3171796 | 0.83 | MEN1 (0.45) | ALDH1A1TDP1MAPTHTTRAB9A | |
| SCHEMBL1936346 | 0.81 | KMO (0.55) | ALDH1A1MAPT | |
| SCHEMBL14287191 | 0.80 | MAPT (0.56) | ALDH1A1TDP1MAPTTNFHTT | |
| SCHEMBL28913472 | 0.79 | ALDH1A1 (0.49) | ALDH1A1MAPTHTTRAB9ACYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4633734-A1 | COMPOUNDS, COMPOSITIONS, AND MEZHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN MISFOLDING | Wavebreak Therapeutics, LLC (US) | 2025-10-22 | — | — | EP | disclosed |
| WO-2024129881-A1 | COMPOUNDS, COMPOSITIONS, AND MEZHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN MISFOLDING | WAVEBREAK THERAPEUTICS LIMITED (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20230416815-A1 | METHOD FOR LABELING NUCLEIC ACID | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2023-12-28 | — | — | US | disclosed |
| EP-4211262-A1 | METHOD FOR LABELING NUCLEIC ACID | Cambridge Enterprise Limited (GB) | 2023-07-19 | — | — | EP | disclosed |
| CN-116323603-A | Method for labeling nucleic acids | 剑桥实业有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-110545817-B | GSK-3 inhibitors | 百时美施贵宝公司 | 2022-11-15 | — | — | CN | disclosed |
| CN-110225912-B | GSK-3 inhibitors | 百时美施贵宝公司 | 2022-10-21 | — | — | CN | disclosed |
| WO-2022053718-A1 | METHOD FOR LABELING NUCLEIC ACID | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2022-03-17 | — | — | WO | disclosed |
| EP-3544980-B1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3544613-B1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-09 | — | — | EP | disclosed |
| CN-110545817-A | GSK-3 inhibitors | SQUIBB BRISTOL MYERS COMPANY | 2019-12-06 | — | — | CN | disclosed |
| US-20190315714-A1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190315714-A1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-17 | — | — | US | disclosed |
| EP-3544980-A1 | GSK-3 INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-3544613-A1 | GSK-3 INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-10-02 | — | — | EP | disclosed |
| US-20190276463-A1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-09-12 | — | — | US | disclosed |
| US-20190276463-A1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-09-12 | — | — | US | disclosed |
| CN-110225912-A | GSK-3 inhibitor | 百时美施贵宝公司 | 2019-09-10 | — | — | CN | disclosed |
| WO-2018098411-A1 | GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098412-A1 | GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416815-A1 | METHOD FOR LABELING NUCLEIC ACID | ALKBH1, ALKBH2, NT5C3B | ALDH1A1 476/4885TDP1 171/4885MAPT 3759/4885 |
| US-20190315714-A1 | GSK-3 INHIBITORS | GSK3B, GSK3A, GSKIP | ALDH1A1 4374/4885TDP1 1079/4885MAPT 90/4885 |
| US-20190276463-A1 | GSK-3 INHIBITORS | GSK3B, GSK3A, GSKIP | ALDH1A1 4339/4885TDP1 1102/4885MAPT 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.